Browsing by Author "Sever N."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
    (Springer, 2024) Beypınar İ.; Demir H.; Yaslıkaya Ş.; Köşeci T.; Demir B.; Çolak G.; Ağaoğlu A.B.; Şahbazlar M.; Şancı P.C.; Çabuk D.; Işık U.; Şahin E.; Coşkun A.; Caner B.; Aykut T.; Artaç M.; Duygulu M.E.; Sever N.; Öksüz S.; Turan N.; Aykan M.B.; Tüzün E.K.; Uysal M.; Uğurlu İ.; Sakin A.; Acar C.; Özaşkın D.; Şakalar T.; Keskinkılıç M.; Yavuzşen T.; Köse N.; Ertürk İ.; Yıldırım N.; Balçık O.Y.; Alkan A.; Selvi O.; Erçin E.; Ünal O.Ü.; Karaçin C.
    Purpose: In advanced breast cancer, endocrine therapy is preferred in the absence of visceral crisis. Cyclin-dependent kinase inhibitors (CDKi) are the gold standards. The selection of subsequent treatments after CDKi treatment is still controversial, and the efficacy of everolimus (EVE) combinations is unknown. In this study, we aimed to investigate the efficacy of EVE after CDKi administration in real-life experiences. Method: The study received data from 208 patients from 26 cancer centers. Demographic and histologic features, diagnosis, progression, last visit dates, and toxicities were recorded. This study was a retrospective case series. Results: One hundred and seven patients received palbociclib, while 101 patients received ribociclib as a CDKi. The overall response and disease control rates of EVE combinations were 60% and 88%, respectively. In univariate analysis, the absence of liver metastasis, age > 40 years, better type of response, and immediate treatment after CDKi were related to increased progression-free survival. Liver metastasis and response type were significantly associated with overall survival. In the multivariate analysis, response remained significant in terms of progression-free survival, while response type, liver metastatic disease, and hematologic toxicity were prognostic in terms of overall survival. Conclusion: This study provides evidence of the benefits of EVE combinations after CDKi treatment. EVE combinations may be more appropriate for patients with non-liver metastasis, and the first treatment response shows the benefit of treatment. In addition, immediate treatment after CDKi treatment is more beneficial than later lines of treatment. © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.
  • No Thumbnail Available
    Item
    The Effectiveness of Adjuvant PD-1 Inhibitors in Patients with Surgically Resected Stage III/IV Acral Melanoma
    (Lippincott Williams and Wilkins, 2024) Arak H.; Erkiliç S.; Yaslikaya Ş.; Eylemer Mocan E.; Aktaş G.; Özdemir M.; Semiz H.S.; Kiliçkap S.; Özalp F.R.; Sever Ö.N.; Akdaǧ G.; Aǧaoǧlu A.B.; Özçelik M.; Sari M.; Arcagök M.; Anik H.; Yayla Ş.B.; Sever N.; Açar F.P.; Bayrakçi İ.; Turhal S.; Ayhan M.; Kuş T.
    Our aim was to assess the efficacy of adjuvant programmed cell death protein-1 (PD-1) inhibitors and compare the other adjuvant treatments in patients with surgically resected stage III or IV acral melanoma. This study is a multicenter, retrospective analysis. We included 114 patients with stage III or IV acral malignant melanoma who underwent surgery within the past 10 years. We analyzed the effect of adjuvant programmed cell death protein-1 inhibitors on disease-free survival (DFS). The mean follow-up was 40 months, during which 69 (59.5%) patients experienced recurrence. Among the participants, 64 (56.1%) received systemic adjuvant therapy. Specifically, 48.4% received anti-PD-1 therapy, 29.7% received interferon, 14.1% received tezozolomide, and 7.8% received B-Raf proto-oncogene/mitogen-activated protein kinase inhibitors. Patients who received adjuvant therapy had a median DFS of 24 (10.9-37.2) months, whereas those who did not receive adjuvant therapy had a median DFS of 15 (9.8-20.2) months. Multivariate analysis for DFS revealed that the receipt of adjuvant therapy and lymph node metastasis stage were independent significant parameters (P = 0.021, P = 0.018, respectively). No statistically significant difference was observed for DFS between programmed cell death protein-1 inhibitor treatment and other adjuvant treatments. Regarding overall survival (OS), patients who received adjuvant treatment had a median OS of 71 (30.4-111.7) months, whereas those who did not receive adjuvant treatment had a median OS of 38 (16.7-59.3; P = 0.023) months. In addition, there were no significant differences in OS observed between various adjuvant treatment agents (P = 0.122). In our study, we have shown that adjuvant therapy had a positive effect on both DFS and OS in patients with stages III-IV acral melanoma who underwent curative intent surgery. Notably, we found no significant differences between anti-PD-1 therapy and other adjuvant therapies. © 2024 Lippincott Williams and Wilkins. All rights reserved.
  • No Thumbnail Available
    Item
    Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group
    (Multidisciplinary Digital Publishing Institute (MDPI), 2025) Sever N.; Şimşek F.; Onur İ.D.; Arvas H.; Guliyev T.; Şakalar T.; Çiçek C.M.; Orman S.; Çetin E.B.; Kayaş K.; Akbaş S.; Ağyol Y.; Güren A.K.; Erel P.; Kocaaslan E.; Paçacı B.; Tunç M.A.; Çelebi A.; Majidova N.; Durnalı A.; Şimşek M.; Şahbazlar M.; Işık S.; Arıkan R.; Ercelep Ö.; Sarı M.; Köstek O.; Bayoğu İ.V.
    Background: Osteosarcoma is a rare but aggressive bone malignancy. Despite advances in multimodal therapy, survival remains suboptimal, highlighting the need for prognostic markers to guide treatment. Methods: This study included 162 osteosarcoma patients who received neoadjuvant chemotherapy followed by surgery between January 2009 and March 2024. Patients received either double (cisplatin + doxorubicin) or triple (MAP or PEI) chemotherapy. Survival analyses were conducted using Kaplan–Meier curves, log-rank tests, and Cox proportional hazards models. Results: The median age was 20 years (IQR: 18–29), and 53.1% were male. Patients who received triple chemotherapy regimens demonstrated significantly longer overall survival (OS) compared to those on doublet regimens. High tumor necrosis rates (>90%) and negative surgical margins were strongly associated with improved OS, while metastatic disease at diagnosis, elevated alkaline phosphatase (ALP), and male gender were linked to poorer survival. Multivariate analysis identified adjuvant therapy, age under 18, high necrosis rate, negative margins, and normal ALP as significant OS predictors. Conclusions: Triple-agent chemotherapy, necrosis rate ≥90 and negative surgical margins are strongly associated with prolonged survival in osteosarcoma. The key prognostic indicators such as ALP levels, surgical margins and age at diagnosis should guide personalized treatment strategies to improve outcomes in curable patients. © 2025 by the authors.